Results 61 to 70 of about 280,213 (189)

Implementing physician‐led medication reviews for patients with diabetes and severe mental disorder: A randomized controlled trial

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Patients with severe mental disorder and diabetes may be exposed to inappropriate polypharmacy increasing the risk of side effects and drug interactions. Although medication reviews may facilitate short‐term deprescribing, they are not known to affect clinical outcomes.
Johan Frederik Mebus Meyer Christensen   +2 more
wiley   +1 more source

Towards greener prescribing? Swedish general practitioners' support for policies to reduce pharmaceutical pollution

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing pharmaceuticals is essential to improve health, but it also has substantial environmental impact. This study investigated the extent to which Swedish general practitioners (GPs) are willing to integrate environmental aspects into treatment decisions and their opinions on policies to reduce pharmaceutical pollution.
Johanna Villén   +5 more
wiley   +1 more source

Developing the Inpatient Mental Health Pharmaceutical Assessment and Care Tool (IMPACT) for use by UK mental health pharmacy teams—a modified Delphi study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To develop an evidence‐ and consensus‐based patient prioritization tool for use by UK mental health inpatient pharmacy teams. Methods A modified‐Delphi technique was used to obtain experts' agreement on the content, design and practical use of the patient prioritization tool.
Fatima Q. Alshaikhmubarak   +3 more
wiley   +1 more source

Development of the NES online palliative care medicines training series for health and social care support staff [PDF]

open access: yes, 2017
Previous Macmillan Cancer Support and Health Board funded palliative care pharmacy service evaluations in NHS Greater Glasgow & Clyde (urban) and NHS Highland (rural) (1-4) observed a steady integration of the community pharmacy team into local ...
Akram, Gazala   +8 more
core  

A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Amgevita is a licensed biosimilar to adalimumab, having demonstrated high pharmacokinetic and clinical similarity to Humira. Switching to a lower‐cost medicine may elicit a nocebo effect, whereby expectations of poorer efficacy impact outcomes despite pharmacological similarity. This prospective cohort study examined clinical and economic outcomes
Louise Rabbitt   +7 more
wiley   +1 more source

Patient, carer and healthcare professional perspectives on deprescribing in surgical wards: A mixed methods study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The perspectives of patients and healthcare professionals regarding deprescribing in surgical wards within hospital settings are unknown. The aim of this study was to explore current practices, attitudes and the enablers and barriers to deprescribing in hospital for older surgical inpatients from the perspectives of doctors, pharmacists ...
Bonnie M. Liu   +5 more
wiley   +1 more source

Community pharmacy services during the COVID-19 pandemic: Insights from providers and policy makers. [PDF]

open access: yesExplor Res Clin Soc Pharm, 2023
Warr H   +3 more
europepmc   +1 more source

Medications, epilepsy and climate change: Added layers of complexity

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Climate change—the global crisis with pervasive health impacts—has adverse consequences for people with epilepsy (PWE) who have low quality of life due to poor seizure control, socioeconomic disadvantages and comorbidities. This review focuses on the potential effects of climate change on the pharmacological characteristics of antiseizure medications ...
Medine I. Gulcebi   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy